ElutiaELUT
About: Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.
Employees: 51
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
71% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 7
0.13% more ownership
Funds ownership: 47.18% [Q1] → 47.31% (+0.13%) [Q2]
9% less funds holding
Funds holding: 32 [Q1] → 29 (-3) [Q2]
20% less capital invested
Capital invested by funds: $44.6M [Q1] → $35.5M (-$9.08M) [Q2]
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
100% less funds holding in top 10
Funds holding in top 10: 3 [Q1] → 0 (-3) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for ELUT.
Financial journalist opinion
Based on 4 articles about ELUT published over the past 30 days
